Plain-English translation of NCT07657312 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that blocks a specific immune signal, to prevent severe cytokine release syndrome—a dangerous overreaction of the immune system—in patients with relapsed or refractory multiple myeloma who are being treated with or . These newer cancer therapies are effective but can trigger this serious immune reaction. This study aims to find out whether the medication can safely reduce this risk.
and are promising treatments for hard-to-treat blood cancers, but they often cause a dangerous condition where the immune system overreacts and floods the body with inflammatory chemicals. Researchers want to know if this preventive medication can block that overreaction and make these cancer treatments safer for more patients.
You likely qualify if…
You likely don't qualify if…
You will receive the preventive medication as an intravenous infusion about 2–4 hours before your first dose of the cancer treatment. You will then receive the cancer treatment as injections under the skin on specific days (days 1, 3, 5, 15, 22, and 28 of the first treatment cycle). Throughout the first month, you will have blood tests and may have a bone marrow biopsy and imaging scans to check how you are responding and monitor for side effects. After the first month of treatment, you will have a follow-up visit to see how you are doing.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States